Is Molina Healthcare (MOH) Fairly Valued Following RBC’s 2027 Earnings Growth View?

RBC Capital’s latest commentary on Molina Healthcare (MOH) centers on what it describes as a clear earnings path through 2027. The firm highlights operating leverage and cost discipline despite ongoing questions around Medicaid rate levels.

See our latest analysis for Molina Healthcare.

Molina Healthcare’s recent momentum stands out, with a 45.12% 90 day share price return and a 9.38% 30 day share price return lifting the stock to $201.42, even though the 1 year total shareholder return has declined 31.52%.

If Molina Healthcare’s move has caught your attention, this can be a good moment to widen your watchlist and look at other healthcare related opportunities via 38 healthcare AI stocks

With Molina Healthcare trading at $201.42, well above the average analyst price target but flagged with a wide intrinsic discount, investors face a key question: is the stock undervalued or already pricing in future growth?

Most Popular Narrative: 34.5% Overvalued

Compared with Molina Healthcare’s last close at $201.42, the most widely followed narrative points to a fair value of $149.76, using a 6.98% discount rate to frame that gap.

Molina's successful track record of winning RFPs, including new contracts in Nevada and Illinois, is expected to drive significant revenue growth, with projected incremental annual premium revenue of approximately $800 million. This should positively impact revenue and EPS growth.

Read the complete narrative.

Curious how a company with modest margin assumptions can still justify a higher future earnings base and valuation multiple? The narrative leans heavily on projected top line expansion and disciplined cost control. The tension between slower revenue forecasts and higher implied P/E is where the real story sits.

Result: Fair Value of $149.76 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in Molina Healthcare still need to weigh risks such as potential Medicaid funding cuts and higher medical costs, which could pressure margins and unsettle earnings expectations.

Find out about the key risks to this Molina Healthcare narrative.

Another View: SWS DCF Puts Molina Healthcare In A Different Light

The analyst narrative pegs Molina Healthcare at a fair value of $149.76 and describes the stock as 34.5% overvalued at $201.42. Our DCF model presents a different picture, with an estimated future cash flow value of $620.24, which implies a large gap that investors need to reconcile.

If earnings-based price targets and long-term cash flow estimates are pointing in opposite directions, which set of assumptions do you consider more useful for evaluating Molina Healthcare?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Molina Healthcare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and concern around Molina Healthcare feels familiar, take a moment now to review the full picture yourself, balancing the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Molina Healthcare?

Do not stop with Molina Healthcare. Broaden your watchlist now using focused stock ideas so you are not relying on a single story or sector.

• Target stability first and put capital to work in companies that score well on resilience with the 69 resilient stocks with low risk scores
• Hunt for value opportunities that pair quality fundamentals with appealing pricing by using the 44 high quality undervalued stocks
• Spot potential long term compounders early by checking the screener containing 18 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com